{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T16:33:10Z","timestamp":1786465990545,"version":"build-2736575974"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004954","name":"Augustinus Fonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004954","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>PLA2R immunohistochemistry (IHC) and serum anti-PLA2R antibodies are key diagnostic tools in PLA2R-associated membranous nephropathy (MN). However, diagnostic performance and inter-observer reproducibility of PLA2R IHC across different laboratory protocols and cut-offs remain insufficiently validated. We performed local validation of two routine PLA2R IHC protocols and report the methodological considerations that emerged, including the interaction between cut-off selection, diagnostic accuracy, and observer reproducibility.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In a multi-laboratory study, kidney biopsies from patients with primary MN (pMN), secondary MN, and non-MN controls were stained using two routine PLA2R IHC protocols (Aarhus University Hospital [AUH] and Herlev Hospital [HEH]). Seven blinded observers scored granular capillary wall staining intensity on a 0\u20133 scale. Diagnostic performance was assessed at a prespecified cut-off (\u2265\u20092) and at protocol-specific optimal cut-offs determined by Youden\u2019s J index. Inter-observer agreement for the ordinal scale was quantified using intraclass correlation coefficients (ICC). Reproducibility of dichotomized classifications was evaluated using the ONEST framework, examining overall percent agreement (OPA) across increasing numbers of observers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At the prespecified cut-off (\u2265\u20092), sensitivity\/specificity was 70%\/70% for AUH and 55%\/100% for HEH. Applying Youden\u2019s J calculated optimal cut-offs (AUH: \u22653; HEH: \u22651) yielded sensitivity\/specificity of 65%\/100% for AUH and 65%\/93% for HEH. Single-rating reliability was good-to-excellent overall [ICC (2,1)\u2009=\u20090.85], with protocol-specific differences (AUH\u2009=\u20090.78; HEH\u2009=\u20090.93), and the seven-observer panel demonstrated excellent reliability [ICC (2,7)\u2009=\u20090.96\u20130.99]. ONEST analyses demonstrated higher agreement for HEH at the prespecified cut-off (OPA 93% vs. 60%) and earlier stabilization of agreement curves, whereas AUH remained sensitive to panel size throughout the seven-observer range. Diagnostic accuracy and reproducibility were not fully aligned for the HEH protocol: Youden\u2019s J favored cut-off \u2265\u20091, whereas reproducibility was highest at \u2265\u20092.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>PLA2R IHC provides clinically useful diagnostic information for PLA2R-associated MN, but performance and reproducibility are protocol-dependent and were optimized at different cut-offs. Laboratories should therefore validate both dimensions locally rather than adopting a single fixed cut-off. We propose a stepwise framework combining Youden\u2019s J and ONEST as a practical guide for laboratories implementing PLA2R IHC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-026-05233-0","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T17:35:37Z","timestamp":1785260137000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Diagnostic performance and inter-observer reproducibility of glomerular PLA2R immunohistochemistry in primary membranous nephropathy: a multi-laboratory blinded observer study"],"prefix":"10.1186","volume":"27","author":[{"given":"Birgitte G.","family":"Tougaard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren","family":"Krag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Gravesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mie Emilie","family":"Kristensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Madsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lene Buhl","family":"Riis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorrit","family":"Krustrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Ivarsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"issue":"4S","key":"5233_CR1","first-page":"S1","volume":"100","author":"Kidney Disease","year":"2021","unstructured":"Kidney Disease. Improving Global Outcomes Glomerular Diseases Work G. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1\u2013276.","journal-title":"Kidney Int"},{"issue":"1","key":"5233_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa0810457","volume":"361","author":"LH Beck Jr","year":"2009","unstructured":"Beck LH Jr., Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361(1):11\u201321.","journal-title":"N Engl J Med"},{"issue":"6","key":"5233_CR3","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1016\/j.kint.2019.07.014","volume":"96","author":"AE an de Logt","year":"2019","unstructured":"van de Logt AE, Fresquet M, Wetzels JF, Brenchley P. The anti-PLA2R antibody in membranous nephropathy: what we know and what is still a decade after its discovery. Kidney Int. 2019;96(6):1292\u2013302.","journal-title":"Kidney Int"},{"issue":"9","key":"5233_CR4","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1038\/s41379-019-0267-z","volume":"32","author":"T Wiech","year":"2019","unstructured":"Wiech T, Stahl RAK, Hoxha E. Diagnostic role of renal biopsy in PLA(2)R1-antibody-positive patients with nephrotic syndrome. Mod Pathol. 2019;32(9):1320\u20138.","journal-title":"Mod Pathol"},{"issue":"7","key":"5233_CR5","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/ki.2012.209","volume":"82","author":"E Hoxha","year":"2012","unstructured":"Hoxha E, Kneissler U, Stege G, Zahner G, Thiele I, Panzer U, et al. Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy. Kidney Int. 2012;82(7):797\u2013804.","journal-title":"Kidney Int"},{"key":"5233_CR6","doi-asserted-by":"crossref","unstructured":"Zand L, Fervenza FC, Sethi S. What\u2019s new in membranous nephropathy and how to incorporate new antigen discoveries into clinical practice: a review. Am J Kidney Dis. 2026 Jan;87(1):93-101.","DOI":"10.1053\/j.ajkd.2025.08.013"},{"issue":"1","key":"5233_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000453675","volume":"7","author":"S Roy","year":"2017","unstructured":"Roy S, Korula A, Basu G, Jacob S, Varughese S, Tamilarasi V. Immunohistochemical Glomerular Expression of Phospholipase A2 Receptor in Primary and Secondary Membranous Nephropathy: A Retrospective Study in an Indian Cohort with Clinicopathological Correlations. Nephron Extra. 2017;7(1):1\u20139.","journal-title":"Nephron Extra"},{"issue":"1","key":"5233_CR8","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12882-021-02338-6","volume":"22","author":"M Arghiani","year":"2021","unstructured":"Arghiani M, Zamani BH, Nazemian F, Samadi S, Afsharian MS, Habibzadeh M, et al. A cohort study of membranous nephropathy, primary or secondary. BMC Nephrol. 2021;22(1):138.","journal-title":"BMC Nephrol"},{"issue":"1","key":"5233_CR9","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12882-023-03273-4","volume":"24","author":"D Bajcsi","year":"2023","unstructured":"Bajcsi D, Bito L, Turkevi-Nagy S, Nyari T, Kemeny E, Legrady P, et al. The value of PLA2R antigen and IgG subclass staining relative to anti-PLA2R seropositivity in the differential diagnosis of membranous nephropathy. BMC Nephrol. 2023;24(1):230.","journal-title":"BMC Nephrol"},{"issue":"6","key":"5233_CR10","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1097\/PAI.0000000000000892","volume":"29","author":"R Del Sordo","year":"2021","unstructured":"Del Sordo R, Covarelli C, Brugnano R, Sciri R, Bellezza G, Mandarano M, et al. PLA2R Immunohistochemistry Staining in Membranous Glomerulopathy: A Challenging Stain to Interpret, But a Potentially Useful Diagnostic Tool. Appl Immunohistochem Mol Morphol. 2021;29(6):414\u201321.","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"5","key":"5233_CR11","doi-asserted-by":"publisher","first-page":"e0156263","DOI":"10.1371\/journal.pone.0156263","volume":"11","author":"HR Dong","year":"2016","unstructured":"Dong HR, Wang YY, Cheng XH, Wang GQ, Sun LJ, Cheng H, et al. Retrospective Study of Phospholipase A2 Receptor and IgG Subclasses in Glomerular Deposits in Chinese Patients with Membranous Nephropathy. PLoS ONE. 2016;11(5):e0156263.","journal-title":"PLoS ONE"},{"issue":"5","key":"5233_CR12","doi-asserted-by":"publisher","first-page":"353","DOI":"10.4103\/ijn.IJN_79_17","volume":"27","author":"A Gudipati","year":"2017","unstructured":"Gudipati A, Uppin MS, Kalidindi RK, Swarnalatha G, Das U, Taduri G, et al. Immunohistochemical Analysis of Anti-phospholipase A2 Receptor Antibody on Renal Biopsies: A Single Tertiary Care Center Study. Indian J Nephrol. 2017;27(5):353\u20138.","journal-title":"Indian J Nephrol"},{"issue":"4","key":"5233_CR13","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s40620-018-0489-z","volume":"31","author":"V L\u2019Imperio","year":"2018","unstructured":"L\u2019Imperio V, Pieruzzi F, Sinico RA, Nebuloni M, Granata A, Smith A, et al. Routine immunohistochemical staining in membranous nephropathy: in situ detection of phospholipase A2 receptor and thrombospondin type 1 containing 7A domain. J Nephrol. 2018;31(4):543\u201350.","journal-title":"J Nephrol"},{"issue":"1","key":"5233_CR14","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12882-020-02216-7","volume":"22","author":"BF Lwezaula","year":"2021","unstructured":"Lwezaula BF, Ameh OI, Ekrikpo UE, Botha FC, Okpechi-Samuel US, Wearne N, et al. Diagnostic performance of glomerular PLA2R and THSD7A antibodies in biopsy-confirmed primary membranous nephropathy in South Africans. BMC Nephrol. 2021;22(1):15.","journal-title":"BMC Nephrol"},{"issue":"3","key":"5233_CR15","first-page":"353","volume":"34","author":"A Segarra-Medrano","year":"2014","unstructured":"Segarra-Medrano A, Jatem-Escalante E, Quiles-P\u00e9rez MT, Salcedo MT, Arbos-Via MA, Ostos H, et al. Prevalence, diagnostic value, and clinical characteristics associated with the presence of circulating levels and renal deposits of antibodies against the M-type phospholipase A2 receptor in idiopathic membranous nephropathy. Nefrologia. 2014;34(3):353\u20139.","journal-title":"Nefrologia"},{"issue":"1","key":"5233_CR16","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1186\/s12882-017-0636-0","volume":"18","author":"J Wang","year":"2017","unstructured":"Wang J, Xie Q, Sun Z, Xu N, Li Y, Wang L, et al. Response to immunosuppressive therapy in PLA(2) R-associated and non-PLA(2) R-associated idiopathic membranous nephropathy: a retrospective, multicenter cohort study. BMC Nephrol. 2017;18(1):227.","journal-title":"BMC Nephrol"},{"issue":"8","key":"5233_CR17","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1097\/PAI.0000000000000460","volume":"26","author":"MK Yeo","year":"2018","unstructured":"Yeo MK, Kim YH, Choi DE, Choi SY, Kim KH, Suh KS. The Usefulness of Phospholipase A2 Receptor and IgG4 Detection in Differentiating Primary Membranous Nephropathy From Secondary Membranous Nephropathy in Renal Biopsy. Appl Immunohistochem Mol Morphol. 2018;26(8):591\u20138.","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"1","key":"5233_CR18","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1080\/0886022X.2020.1792315","volume":"42","author":"P Yin","year":"2020","unstructured":"Yin P, Wang J, Liang W, Zhan L, Liu Y, Lin J, et al. Outcomes of primary membranous nephropathy based on serum anti-phospholipase A2 receptor antibodies and glomerular phospholipase A2 receptor antigen status: a retrospective cohort study. Ren Fail. 2020;42(1):675\u201383.","journal-title":"Ren Fail"},{"issue":"6","key":"5233_CR19","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1007\/s00428-021-03172-9","volume":"479","author":"B Cserni","year":"2021","unstructured":"Cserni B, Bori R, Csorgo E, Olah-Nemeth O, Pancsa T, Sejben A, et al. The additional value of ONEST (Observers Needed to Evaluate Subjective Tests) in assessing reproducibility of oestrogen receptor, progesterone receptor, and Ki67 classification in breast cancer. Virchows Arch. 2021;479(6):1101\u20139.","journal-title":"Virchows Arch"},{"issue":"2","key":"5233_CR20","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jcm.2016.02.012","volume":"15","author":"TK Koo","year":"2016","unstructured":"Koo TK, Li MY. A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability Research. J Chiropr Med. 2016;15(2):155\u201363.","journal-title":"J Chiropr Med"},{"issue":"1","key":"5233_CR21","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","volume":"3","author":"WJ Youden","year":"1950","unstructured":"Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32\u20135.","journal-title":"Cancer"},{"key":"5233_CR22","doi-asserted-by":"publisher","first-page":"h5527","DOI":"10.1136\/bmj.h5527","volume":"351","author":"PM Bossuyt","year":"2015","unstructured":"Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, et al. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. BMJ. 2015;351:h5527.","journal-title":"BMJ"},{"issue":"8","key":"5233_CR23","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1093\/ndt\/gfaf012","volume":"40","author":"O Ragy","year":"2025","unstructured":"Ragy O, Abass W, Kanigicherla DAK, Shinkins B, Bestall J, King N, et al. PLA2R autoantibodies, a multifaceted biomarker in nephrotic syndrome and membranous nephropathy. Nephrol Dial Transpl. 2025;40(8):1458\u201369.","journal-title":"Nephrol Dial Transpl"},{"issue":"3","key":"5233_CR24","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.kint.2025.04.032","volume":"108","author":"L Zand","year":"2025","unstructured":"Zand L, Russo I, Vargas-Brochero MJ, Nasr SH, Madden B, Theis JD, et al. Phospholipase A2 receptor-positive membranous nephropathy detected by laser microdissection and mass spectrometry in patients negative by immunofluorescence for phospholipase A2 receptor on kidney biopsy. Kidney Int. 2025;108(3):481\u20134.","journal-title":"Kidney Int"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-026-05233-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-05233-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-05233-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T15:26:02Z","timestamp":1786461962000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-026-05233-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5233"],"URL":"https:\/\/doi.org\/10.1186\/s12882-026-05233-0","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"assertion":[{"value":"23 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval: The Regional Ethics Committee of the Central Denmark Region, Denmark (DNVK 74249). Consent to participate was not obtained due to the nature of the retrospective design, and this was approved by the Regional Ethics Committee. This study was conducted in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"467"}}